๐Ÿ‡ฎ๐Ÿ‡ชIreland
16ยฐC Partly Cloudy ยท Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Canterbury
Clinical trial register · United Kingdom · industry-sponsored

Clinical Trials in Canterbury

Every industry-sponsored study on the ClinicalTrials.gov registry that lists a UK site and is open, about to open, active-but-closed, or enrolling by invitation. This deliberately excludes academic and other non-industry sponsors โ€” the full UK registry across all sponsors is far larger. UK studies may also be registered separately on ISRCTN.

Download CSV
Source: ClinicalTrials.gov. Complete coverage of the industry-sponsored slice โ€” all 2846 matching records are in this view (non-industry sponsors are out of scope by design, not truncated). Synced 21 Sep 2026, 03:15 UTC
2846
Studies in scope
industry-sponsored, all four open statuses
1377
Recruiting now
open to new participants
539
Lead sponsors
across recruiting studies
Top sites
London 2003 Manchester 674 Birmingham 469 Glasgow 437 Cambridge 416
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
BeOne Medicines3 AstraZeneca3 Janssen Research & Development, LLC3 ReCor Medical, Inc.2 Sanofi2
Site city
London2003 Manchester674 Birmingham469 Glasgow437 Cambridge416
All 426 cities
Target enrolment
to
35 of 2846 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
UK sites
Start
Recruiting
A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma
NCT07258511Multiple Myeloma
Janssen Research & Development, LLC
Phase 3
400
Canterbury, Cardiff, Dundee, London, Nottingham, Portsmouth, Sutton
2026-02-04
Recruiting
AZD5335 vs. Mirvetuximab Soravtansine in FRฮฑ-high and AZD5335 vs. Chemotherapy in FRฮฑ-low Platinum-resistant Ovarian Cancer
NCT07218809Epithelial Ovarian Cancer
AstraZeneca
Phase 3
1,100
Barrow in Furness, Birmingham, Cambridge, Canterbury, Cardiff, Edinburgh, Greater London, London
2025-12-29
Recruiting
Phase III Study of Ivonescimab or Bevacizumab Combined With FOLFOX in Patients With Metastatic Colorectal Cancer
NCT07228832Metastatic Colorectal Cancer (CRC)
Summit Therapeutics
Phase 3
600
Canterbury, London, Aberdeen, Edinburgh, Liverpool, Manchester
2025-11-18
Recruiting
A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer
NCT06793215Non-Small Cell Lung Cancer, KRAS G12C Lung Cancer
Hoffmann-La Roche
Phase 3
600
Blackpool, Bristol, Canterbury, Cardiff, Hull, London, Maidstone, Oxford
2025-10-24
Recruiting
A Study to Evaluate the Safety and Efficacy of Tacabrutideg (BGB-16673) Compared to Pirtobrutinib in Adults With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
NCT06973187Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
BeOne Medicines
Phase 3
500
Brighton, Canterbury, Norwich, Oxford, Roundhay, Salisbury
2025-09-04
Recruiting
Puxitatug Samrotecan (AZD8205) Monotherapy vs Chemotherapy in B7-H4-selected Endometrial Cancer (Bluestar-Endometrial01)
NCT07044336Endometrial Cancer, Malignant Solid Tumour
AstraZeneca
Phase 3
800
Bebington, Canterbury, Derby, London, Manchester, Northwood, Truro
2025-08-01
Recruiting
A Study to Compare the Efficacy and Safety of Golcadomide in Combination With Rituximab (Golca + R) vs Investigator's Choice in Participants With Relapsed/Refractory Follicular Lymphoma Who Have Received at Least 1 Prior Line of Systemic Therapy (GOLSEEK-4)
NCT06911502Follicular Lymphoma
Celgene
Phase 3
400
Cringleford, Canterbury, London, Manchester
2025-07-28
Recruiting
A Study of Mezagitamab in Adults With Kidney Condition Called IgA Nephropathy
NCT06963827Kidney Disease
Takeda
Phase 3
347
London, Birmingham, Canterbury, Hull, Leicester, Nottingham, Preston, Sheffield
2025-07-15
Recruiting
A Study of Bleximenib, Venetoclax and Azacitidine For Treatment of Participants With Newly Diagnosed Acute Myeloid Leukemia (AML)
NCT06852222Leukemia, Myeloid, Acute
Janssen Research & Development, LLC
Phase 3
600
Brighton, Cambridge, Canterbury, Colchester, Edinburgh, Liverpool, London, Plymouth
2025-06-04
Recruiting
A Phase III Renal Outcomes and Cardiovascular Mortality Study to Investigate the Efficacy and Safety of Baxdrostat in Combination With Dapagliflozin in Participants With Chronic Kidney Disease and High Blood Pressure
NCT06742723Chronic Kidney Disease and Hypertension
AstraZeneca
Phase 3
5,000
Bradford, Bristol, Canterbury, Cardiff, Dundee, Glasgow, Hounslow, London
2025-03-03
Active, closed
A Study to Evaluate the Efficacy and Safety of Golcadomide in Combination With Rituximab in Participants With Newly Diagnosed Advanced Stage Follicular Lymphoma
NCT06425302Lymphoma, Follicular
Celgene
Phase 2
95
Southampton, Canterbury, Edinburgh, Nottingham
2024-08-30
Active, closed
Efficacy and Safety Study of Frexalimab (SAR441344) in Adults With Nonrelapsing Secondary Progressive Multiple Sclerosis
NCT06141486Multiple Sclerosis
Sanofi
Phase 3
943
Gwent, Cardiff, Exeter, London, Newcastle upon Tyne, Inverness, Canterbury, Salford
2023-12-27
Recruiting
Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab Versus Pembrolizumab Alone in Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) โ‰ฅ 50% (MK-2870-007)
NCT06170788Non-small Cell Lung Cancer (NSCLC)
Merck Sharp & Dohme LLC
Phase 3
614
London, Portsmouth, Canterbury, Central Middlesbrough
2023-12-15
Active, closed
Efficacy and Safety Studies of Frexalimab (SAR441344) in Adults With Relapsing Forms of Multiple Sclerosis
NCT06141473Multiple Sclerosis
Sanofi
Phase 3
1,655
Exeter, London, Inverness, Canterbury, Salford
2023-12-13
Active, closed
Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Obinutuzumab in Participants With Chronic Lymphocytic Leukemia (CLL)
NCT06073821CLL
BeOne Medicines
Phase 3
652
Bournemouth, Canterbury, Headington, Leeds, Liverpool, London, Norwich, Southampton
2023-11-11
Recruiting
The GORE VBX FORWARD Clinical Study: A Comparison of the GOREยฎ VIABAHNยฎ VBX Balloon Expandable Endoprosthesis to Bare Metal Stenting for Patients With Complex Iliac Occlusive Disease
NCT05811364Aortoiliac Occlusive Disease, Peripheral Arterial Disease
W.L.Gore & Associates
Not applicable
244
Canterbury, London, Southampton
2023-10-17
Active, closed
A Study of Obexelimab in Patients With Warm Autoimmune Hemolytic Anemia (SApHiAre)
NCT05786573Warm Autoimmune Hemolytic Anemia
Zenas BioPharma (USA), LLC
Phase 3
134
Plymouth, Canterbury
2023-09-25
Active, closed
An Open-Label Study Comparing Glofitamab and Polatuzumab Vedotin + Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone Versus Pola-R-CHP in Previously Untreated Patients With Large B-Cell Lymphoma
NCT06047080Large B-Cell Lymphoma
Hoffmann-La Roche
Phase 3
1,130
Barnet, Blackpool, Canterbury, Exeter, Glasgow, Leeds, London, Newcastle
2023-09-18
Active, closed
Avacostar - (PASS)
NCT05897684ANCA-associated Vasculitis
Vifor Fresenius Medical Care Renal Pharma
Observational
507
Birmingham, Bradford, Bristol, Cambridge, Canterbury, Cardiff, Carshalton, Coventry
2023-09-11
Recruiting
GEKO Venous Thromboembolism Prevention Study
NCT05476913Stroke, Acute, Venous Thromboembolism, Deep Vein Thrombosis, Pulmonary Embolism
Firstkind Ltd
Not applicable
1,200
Bury St Edmunds, Bath, Birmingham, Bournemouth, Bury, Cambridge, Canterbury, Chester
2023-07-06
Recruiting
Efficacy and Safety of XyloCore Peritoneal Dialysis Solution.
NCT03994471End Stage Renal Disease
Iperboreal Pharma Srl
Phase 3
170
Birmingham, Bradford, Brighton, Canterbury, London, Oxford, Sheffield, Stoke-on-Trent
2022-12-14
Recruiting
A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma
NCT05552222Multiple Myeloma
Janssen Research & Development, LLC
Phase 3
1,590
Birmingham, Blackpool, Bristol, Cambridge, Canterbury, Edinburgh, London, Wolverhampton
2022-10-25
Recruiting
Post-market Clinical Follow-up (PMCF) Study of the Infinity-Lock Button System for Acromioclavicular Joint Stabilisation
NCT05397210Acromioclavicular; Dislocation
Xiros Ltd
Observational
58
Canterbury, London, Nottingham, Reading
2022-09-26
Recruiting
A Study of the Efficacy and Safety of DMX-200 in Patients With FSGS Who Are Receiving an ARB
NCT05183646FSGS
Dimerix Bioscience Pty Ltd
Phase 3
286
Birmingham, Bristol, Canterbury, Carshalton, Coventry, Glasgow, Leicester, London
2022-05-30
Recruiting
The "Global Paradise System" Registry
NCT05027685Hypertension
ReCor Medical, Inc.
Observational
3,000
Bournemouth, Canterbury, Cardiff, Dudley, Glasgow, Hull, London, Newcastle
2022-01-13
Rows per page Showing 1–25 of 35
1 2 Next
Cite this view

Priya Life Science (2026). Clinical trial register: industry-sponsored studies with a UK investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 21 September 2026. https://priyalifescience.com/clinical-trials-uk/city/canterbury

Query this register directly
GET /api/trials?country=uk&status=recruiting&format=json Try it now →
Listing here is informational and not medical advice; eligibility is determined by each study team. Compare pay for the teams running these studies in the UK Pharma Salary Guide, or see the Ireland, EU and USA registers.